Company intelligence / Profile preview
Accro Bioscience
Suzhou（苏州）, Jiangsu Province（江苏省）, 中国（China）accropeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Accro Bioscience has advanced multiple small molecule programs into clinical trials. AC-101 has completed Phase I with strong safety/PK data and is in Phase Ib for UC; AC-201 is in Phase II for psoriasis and NIU; AC-003 has completed Phase I with positive results and is in aGVHD trials. The company holds global rights to its assets with over 20 patents issued worldwide
- Therapeutic areas
- GastroenterologyOphthalmologyImmunologyDermatology
- Modalities
- Small molecules (notably selective kinase inhibitors such as RIPK2, TYK2/JAK1, and RIPK1 inhibitors)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Accro Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Accro Bioscience.